-
Alcaraz withdraws from Cincinnati Masters with wrist injury
-
Kgatlana strikes as South Africa reach WAFCON quarter-finals
-
SpaceX revenue jumps 92% in first earnings report, but shares slide
-
Pakistan close on series-levelling win against West Indies
-
US eyes Hormuz deal 'today or tomorrow' as ship sinks in Red Sea
-
Paramount CEO says politics fueling Warner Bros. merger battle
-
SpaceX revenue jumps 92% in first earnings report
-
Trump's sale of access to Truth Social raises eyebrows
-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
-
Swiss Reusser wins Tour de France Femmes time-trial
-
Arsenal step up bid to sign Newcastle's Guimaraes: reports
-
Hundreds flee homes after Guatemala's Fuego volcano erupts
-
Gazans hold mass funeral for those killed during war
-
Thousands pay tribute to Italian football legend Baresi
-
WHO pleads for more support to tackle Ebola outbreak
-
Oil drops, stocks hit records on hopes of Hormuz opening
-
Oil drops, stocks gain on hopes of Hormuz opening
-
Renard returns as Ivory Coast coach
-
Infantino faces nervy times to see if challenger emerges
-
Italian garbagemen help recover lost 1 mln euro lottery ticket
-
Greece gains ground against blaze near Athens
-
EU nations patch things up after Ceuta migration discord
-
Oil turns lower, stocks gain on hopes of Hormuz opening
-
US hopeful Hormuz strait deal will be done 'today or tomorrow' after ship hit
-
World Bank warns developing countries to embrace AI or be left behind
-
Infantino's problems mount as Wenger and key FIFA ally turn on him
-
'No decision' on Mudryk future after Chelsea return: Alonso
-
Oil edges higher, stocks gain as investors eye political risks
-
China draws up safety rules for autonomous vehicles
-
Man Utd sign reported record £20mn sponsorship deal for training kit
-
Wenger says scrapping Infantino's World Cup plan was "absolutely necessary"
-
Stokes reveals England coaching ambition
-
Spain confronts EU migration hawks in tense Ceuta talks
-
Cargo ship hit after Trump insists Iran talks could reopen Hormuz today
-
Firefighters hope to contain blaze on Athens outskirts
-
BP profit soars as Mideast war roils energy prices
-
Heatwave divides rich and poor of upmarket Seoul
-
Most stock markets gain, while oil prices edge up after plunge
-
Drone strike on Moscow region kills 5
-
Most stock markets gain, while oil prices edge up after latest plunge
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
M.Ouellet--BTB